Fig. 6.

Co-treatment with COX-1-selective and COX-2-selective inhibitors promoted airway inflammation and Th2 responses in the effector phase of i.n. challenge. Mice were treated with COX inhibitor(s) or vehicle during the i.n. challenge phase. All the animal groups were e.c. sensitized to 10 mg/mL papain via intact ear skin and subsequently i.n. challenged (2.5 μg papain). a Time line. b Airway inflammation. c Th2-attracting chemokines in BAL fluid. d Bronchial DLN cell cytokine responses restimulated in vitro. Data are indicated as the mean ± SD of 5 mice per group (b, c) or that of 3 wells of pooled DLN cells from 3 mice (d), and are representative of 3 independent experiments with similar results. d Detection limits are indicated by dotted lines. *p < 0.05 by the Mann-Whitney U test (b, c: vs. no inhibitors) or ANOVA (d: vs. combination of the 2 inhibitors). COX-1 inhibitor, SC560. COX-2 inhibitor, rofecoxib.; COX, cyclooxygenase; DLN, draining lymph node; e.c., epicutaneous; BAL, bronchial alveolar lavage.